Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Inflammatory Bowel Diseases

Free Subscription 15.04.2019 12 Aliment Pharmacol Ther 1 Clin Gastroenterol Hepatol 3 Dig Dis Sci 1 Dis Colon Rectum 3 Eur J Gastroenterol Hepatol 1 Gastroenterol Hepatol 2 J Crohns Colitis 1 J Immunol 1 JAMA 2 PLoS One 1 Z Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Aliment Pharmacol Ther

1. PAPAMICHAEL K, Cheifetz AS
   Letter: infliximab concentrations during induction therapy-one size does not fit all.
   Aliment Pharmacol Ther. 2018;47:1334-1335.
   PubMed     Text format    
   
   
2. BEN-HORIN S
   Editorial: restoring therapeutic infliximab drug levels in patients with loss of response-pharmacokinetics and anti-drug antibodies as useful guidance tools.
   Aliment Pharmacol Ther. 2018;47:845-846.
   PubMed     Text format    
   
   
3. SHARMA V, Mandavdhare HS, Dutta U
   Letter: mucosal response in discriminating intestinal tuberculosis from Crohn's disease-when to look for it?
   Aliment Pharmacol Ther. 2018;47:859-860.
   PubMed     Text format    
   
   
4. PRATAP MOULI V, Kedia S, Ahuja V
   Letter: mucosal response in discriminating intestinal tuberculosis from Crohn's disease-when to look for it? Authors' reply.
   Aliment Pharmacol Ther. 2018;47:860-861.
   PubMed     Text format    
   
   
5. VAN BODEGRAVEN AA, Boone NW
   Editorial: nocebo effect and switching to biosimilars.
   Aliment Pharmacol Ther. 2018;47:850-851.
   PubMed     Text format    
   
   
6. WILSON A, Jansen LE, Rose RV, Gregor JC, et al
   Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype? Authors' reply.
   Aliment Pharmacol Ther. 2018;47:1044-1045.
   PubMed     Text format    
   
   
7. STRIK AS, D'Haens GR
   Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply.
   Aliment Pharmacol Ther. 2018;47:1041-1042.
   PubMed     Text format    
   
   
8. MACALUSO FS, Orlando R, Renna S, Sapienza C, et al
   Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab.
   Aliment Pharmacol Ther. 2018;47:1040-1041.
   PubMed     Text format    
   
   
9. SPARROW MP
   Editorial: clinical trials in IBD-how much of a difference is enough?
   Aliment Pharmacol Ther. 2018;47:1032-1033.
   PubMed     Text format    
   
   
10. TEICH N, Bruns T, Stallmach A
    Letter: predicting azathioprine-associated pancreatitis in IBD-phenotype or genotype?
    Aliment Pharmacol Ther. 2018;47:1042-1043.
    PubMed     Text format    
    
    
11. LIM MH, Doecke JD, Radford-Smith GL
    Editorial: first among Equals-not for either infliximab or adalimumab in Crohn's disease-yet.
    Aliment Pharmacol Ther. 2018;47:1225-1226.
    PubMed     Text format    
    
    
12. MAK WY, Ng SC
    Editorial: ways to reduce emergency department utilisation among IBD patients.
    Aliment Pharmacol Ther. 2018;47:1325-1326.
    PubMed     Text format    
    
    

    
    Clin Gastroenterol Hepatol

13. ANANTHAKRISHNAN AN
    Reply to letter to the editor: Effect of Accelerated Infliximab Induction on Outcomes of Acute Severe Ulcerative Colitis.
    Clin Gastroenterol Hepatol. 2019 Apr 6. pii: S1542-3565(19)30365.
    PubMed     Text format    
    
    

    
    Dig Dis Sci

14. BIAN Y, Liu P, Zhong J, Hu Y, et al
    Quercetin Attenuates Adhesion Molecule Expression in Intestinal Microvascular Endothelial Cells by Modulating Multiple Pathways.
    Dig Dis Sci. 2018;63:3297-3304.
    PubMed     Text format     Abstract available
    
    
15. GAO X, Li J, Chen M
    Effect of Homocysteine on the Differentiation of CD4(+) T Cells into Th17 Cells.
    Dig Dis Sci. 2018;63:3339-3347.
    PubMed     Text format     Abstract available
    
    
16. HAKIM S, Ramireddy S, Amin M, Gebara S, et al
    Preoperative Misdiagnosis of Intestinal Behcet's Syndrome as Crohn's Disease Based on Superficial Colonoscopic Biopsies: Case Report and Systematic Review.
    Dig Dis Sci. 2018;63:3509-3515.
    PubMed     Text format    
    
    

    
    Dis Colon Rectum

17. SHO S, Russell MM
    Influence of Sex in the Management of Ulcerative Colitis.
    Dis Colon Rectum. 2019;62:517-518.
    PubMed     Text format    
    
    

    
    Eur J Gastroenterol Hepatol

18. VIAZIS N, Pontas C, Karmiris K, Dimas I, et al
    Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece.
    Eur J Gastroenterol Hepatol. 2019 Apr 9. doi: 10.1097/MEG.0000000000001414.
    PubMed     Text format     Abstract available
    
    
19. AKYUZ F, Cavus B, Iliaz R, Soyer OM, et al
    Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
    Eur J Gastroenterol Hepatol. 2019 Apr 5. doi: 10.1097/MEG.0000000000001403.
    PubMed     Text format     Abstract available
    
    
20. ESSMANN J, Keil C, Unruh O, Otte A, et al
    Fecal calprotectin is significantly linked to azathioprine metabolite concentrations in Crohn's disease.
    Eur J Gastroenterol Hepatol. 2019;31:99-108.
    PubMed     Text format     Abstract available
    
    

    
    Gastroenterol Hepatol

21. SEDANO MUNOZ R, Quera Pino R, Ibanez Lazo P, Figueroa Corona C, et al
    Aminosalicylates, thiopurines and methotrexate in inflammatory bowel disease: Is it possible to discontinue the treatment?
    Gastroenterol Hepatol. 2019 Apr 3. pii: S0210-5705(19)30056.
    PubMed     Text format     Abstract available
    
    

    
    J Crohns Colitis

22. LOW END, Mokhtar NM, Wong Z, Raja Ali RA, et al
    Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways.
    J Crohns Colitis. 2019 Jan 11. pii: 5430265. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    
23. CHAPARRO M, Garre A, Guerra Veloz MF, Vazquez JM, et al
    Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease.
    J Crohns Colitis. 2019 Apr 12. pii: 5446199. doi: 10.1093.
    PubMed     Text format     Abstract available
    
    

    
    J Immunol

24. SWAFFORD D, Shanmugam A, Ranganathan P, Hussein MS, et al
    Canonical Wnt Signaling in CD11c(+) APCs Regulates Microbiota-Induced Inflammation and Immune Cell Homeostasis in the Colon.
    J Immunol. 2018;200:3259-3268.
    PubMed     Text format     Abstract available
    
    

    
    JAMA

25. FELD L, Glick LR, Cifu AS
    Diagnosis and Management of Crohn Disease.
    JAMA. 2019 Apr 10. pii: 2730734. doi: 10.1001/jama.2019.3684.
    PubMed     Text format    
    
    

    
    PLoS One

26. MOTOYA S, Watanabe K, Ogata H, Kanai T, et al
    Correction: Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study.
    PLoS One. 2019;14:e0215491.
    PubMed     Text format     Abstract available
    
    
27. MULLER C, Stift A, Argeny S, Bergmann M, et al
    Delta albumin is a better prognostic marker for complications following laparoscopic intestinal resection for Crohn's disease than albumin alone - A retrospective cohort study.
    PLoS One. 2018;13:e0206911.
    PubMed     Text format     Abstract available
    
    

    
    Z Gastroenterol

28. PETRUO VA, Krauss E, Kleist A, Hardt J, et al
    Perceived distress, personality characteristics, coping strategies and psychosocial impairments in a national German multicenter cohort of patients with Crohn's disease and ulcerative colitis.
    Z Gastroenterol. 2019;57:473-483.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: